SCHEMBL4884240

SCHEMBL4884240

COc1cccc(CC(=O)O)c1-c1ccc(C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.45
MMP9 P14780 2/20 0.45
MMP12 P39900 2/20 0.45
HSD17B10 Q99714 1/20 0.44
CD274 Q9NZQ7 1/20 0.43
STING1 Q86WV6 1/20 0.43
CTSA P10619 3/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 1/20 0.41
MMP1 P03956 1/20 0.41
MMP3 P08254 1/20 0.41
MMP8 P22894 1/20 0.41
MMP13 P45452 1/20 0.41
MMP14 P50281 1/20 0.41
MMP16 P51512 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10702420 0.89 FABP3 (0.50) MMP2MMP9MMP12HSD17B10CTSA
SCHEMBL4887267 0.80 AKR1B1 (0.55) MMP2MMP9MMP12MEN1KMT2A
SCHEMBL10969934 0.79 AKR1B1 (0.41) MMP2MMP9MMP12ALDH1A1LMNA
SCHEMBL2310865 0.78 STING1 (0.54) MMP2MMP9MMP12HSD17B10STING1
SCHEMBL10701580 0.78 FABP4 (0.48) CTSAMEN1KMT2ANPC1CA12
SCHEMBL4988220 0.77 FABP3 (0.57) HSD17B10KMT2ANPC1CA12CA1
SCHEMBL1045908 0.77 TNKS (0.46) HSD17B10CA12CA1CA2CA7
SCHEMBL8846122 0.77 NPC1 (0.54) CTSANPC1ALDH1A1POLBSMN1; SMN2
SCHEMBL155982 0.76 HSD17B10 (0.61) HSD17B10MEN1KMT2ANPC1LMNA
SCHEMBL29431297 0.76 HSD17B10 (0.61) HSD17B10MEN1KMT2ANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080319043-A1 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319043-A1 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists CHRM3, CHRM5, CHRM2 MMP2 3968/4885MMP9 2999/4885MMP12 2574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.